Clinical Report: Efficacy and Safety Comparison of Immunomodulatory Treatments for Sepsis
Overview
This systematic review and network meta-analysis evaluated the efficacy and safety of various immunomodulatory treatments for sepsis. Ulinastatin, both alone and in combination with thymosin-α1, demonstrated significant reductions in all-cause mortality and improved clinical outcomes.
Background
Sepsis is a life-threatening condition resulting from a dysregulated immune response to infection, leading to high morbidity and mortality rates. Despite advancements in treatment, the need for effective immunomodulatory therapies remains critical. Understanding the efficacy and safety of these treatments is essential for improving patient outcomes in sepsis management.
Data Highlights
Intervention
Outcome
Effect Size (95% CI)
Ulinastatin
All-cause mortality
RR 0.37 (0.22, 0.59)
Ulinastatin + Thymosin-α1
ICU-LOS
MD −2.91 (−5.39, −0.44)
PUFA
Hospital-LOS
MD −20.55 (−39.81, −0.51)
Ulinastatin
MV duration
MD −4.43 (−8.32, −0.49)
Key Findings
Ulinastatin significantly reduced all-cause mortality compared to other treatments.
Combination of Ulinastatin and Thymosin-α1 decreased ICU length of stay.
PUFA was associated with a shorter hospital length of stay.
Ulinastatin alone and in combination with Thymosin-α1 shortened mechanical ventilation duration.
Ulinastatin and PUFA were linked to fewer serious adverse events.
Clinical Implications
The findings suggest that ulinastatin, particularly in combination with thymosin-α1, may be a beneficial treatment option for reducing mortality in sepsis patients. Clinicians should consider these immunomodulatory therapies while remaining aware of the low certainty of evidence and the need for further research.
Conclusion
This network meta-analysis highlights the potential of specific immunomodulatory treatments in sepsis management, particularly ulinastatin. However, the low certainty of evidence necessitates further large-scale trials to confirm these findings.
